Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 13/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.55 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.52 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.52 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.52 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.52 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.52 |
| ▸ | F2R | P25116 | 9/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195847 | 0.91 | ITGB3 (0.49) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL11489205 | 0.86 | ITGB3 (0.60) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL14303380 | 0.85 | ITGB3 (0.59) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL8278505 | 0.83 | ITGB3 (0.61) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL4191524 | 0.83 | SMYD3 (0.45) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL23978381 | 0.81 | GNAI3 (0.59) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL3459102 | 0.81 | ITGB3 (0.55) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL26067161 | 0.79 | ITGB3 (0.54) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL4203196 | 0.74 | KDM1A (0.41) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL10252946 | 0.74 | TP53 (0.58) | ITGB3ITGA2BGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| CN-101500569-A | HIF hydroxylase inhibitors for treatment of anemia of cancer | FIBROGEN INC (US) | 2009-08-05 | — | — | CN | disclosed |
| CN-101490041-A | 2-heterocycloamino-4-imidazolylpyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | ITGB3 4521/4885ITGA2B 3592/4885GNAI3 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.